Unknown

Dataset Information

The utility of remdesivir in SARS-CoV-2: A single tertiary care center experience from a developing country.


ABSTRACT:

Background

Remdesivir is a monophosphoramidate prodrug of an adenosine analog, and it has a broad-spectrum antiviral activity against paramyxoviruses, flaviviruses, and coronaviruses. Remdesivir is associated with decreased hospital stay and improved outcomes in coronavirus- disease 2019 (COVID-19).

Methodology

Of 846 suspected COVID-19 patients admitted to the hospital, 612 SARS-CoV-2 nasopharyngeal RT-PCR positive patients were evaluated for enrollment in this prospective cohort study. 159 RT-PCR positive patients were given remdesivir. Their clinical, biochemical parameters, hospital stay, and outcomes related to morbidity and mortality were followed.

Results

Out of the 159 patients, 141 recovered after remdesivir use. The Chi-square test for independence examined

SUBMITTER: Malik MI 

PROVIDER: S-EPMC8823973 | biostudies-literature | 2022 Mar

REPOSITORIES: biostudies-literature